These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25695397)

  • 41. Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus.
    Nie J; Liu Y; Huang W; Wang Y
    Viruses; 2016 Apr; 8(4):107. PubMed ID: 27120611
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells.
    Lamprecht RL; Kennedy P; Huddy SM; Bethke S; Hendrikse M; Hitzeroth II; Rybicki EP
    Sci Rep; 2016 Feb; 6():20431. PubMed ID: 26853456
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
    Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®).
    Kemp TJ; Safaeian M; Hildesheim A; Pan Y; Penrose KJ; Porras C; Schiller JT; Lowy DR; Herrero R; Pinto LA
    Vaccine; 2012 Dec; 31(1):165-70. PubMed ID: 23123024
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Distribution of serum antibodies against human papillomavirus 16 and 18 among high-risk women to cervical cancer].
    Fei M; Li J; Du J; You J; Zhang S; He W; Kang L; Zhao F; Qiao Y; Si Y; Fan X; Chen W
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 May; 35(5):514-8. PubMed ID: 25059358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Detection of neutralizing antibodies and DNA of human papillomavirus 16, 18 in women aged 18-45 years in Funing, Jiangsu province].
    Liu W; Wei F; Tang J; Yang S; Gao Y; Wang T; Jiang Y; Li M; Hong Y; Chu K; Chen W; Hu Y; Zhu F
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Mar; 37(3):406-9. PubMed ID: 27005547
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.
    Heijstek MW; Scherpenisse M; Groot N; Tacke C; Schepp RM; Buisman AM; Berbers GA; van der Klis FR; Wulffraat NM
    Ann Rheum Dis; 2014 Aug; 73(8):1500-7. PubMed ID: 23723319
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection.
    Longet S; Schiller JT; Bobst M; Jichlinski P; Nardelli-Haefliger D
    J Virol; 2011 Dec; 85(24):13253-9. PubMed ID: 21976653
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
    Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
    PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Measurement of Human Papillomavirus-Specific Antibodies Using a Pseudovirion-Based ELISA Method.
    Toh ZQ; He L; Chen C; Huang A; Russell FM; Garland SM; Reyburn R; Ratu T; Tuivaga E; Frazer IH; Mulholland EK; Licciardi PV
    Front Immunol; 2020; 11():585768. PubMed ID: 33193410
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unveiling the seroprevalence of human papillomavirus in Guangdong, China: Implications for vaccination strategies.
    Hu X; Chen Y; Lin W; Ruan Q; Chen H; Li X; Deng Y; Liang C; Lin H; Zeng L; Sun N; Zhao W; Chen L; Yang Y; Sun L; He J; Sun J
    J Med Virol; 2024 Sep; 96(9):e29910. PubMed ID: 39228341
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of bead-based immunoassay to quantify neutralizing antibody for human papillomavirus 16 and 18.
    Liu HB; Chaturvedi PK; Battogtokh G; Bang HJ; Kim IW; Kim YW; Park KS; Ahn WS
    Mol Biotechnol; 2013 Jun; 54(2):361-70. PubMed ID: 22669586
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Production of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific Antibodies.
    Wang JW; Matsui K; Pan Y; Kwak K; Peng S; Kemp T; Pinto L; Roden RB
    Curr Protoc Microbiol; 2015 Aug; 38():14B.5.1-26. PubMed ID: 26237105
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine types.
    Panicker G; Rajbhandari I; Gurbaxani BM; Querec TD; Unger ER
    J Immunol Methods; 2015 Feb; 417():107-114. PubMed ID: 25554636
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin.
    Rubio I; Bolchi A; Moretto N; Canali E; Gissmann L; Tommasino M; Müller M; Ottonello S
    Vaccine; 2009 Mar; 27(13):1949-56. PubMed ID: 19368776
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of serum antibodies from women immunized with Gardasil: A study of HPV-18 infection of primary human keratinocytes.
    Wang HK; Wei Q; Moldoveanu Z; Huh WK; Vu HL; Broker TR; Mestecky J; Chow LT
    Vaccine; 2016 Jun; 34(27):3171-3177. PubMed ID: 27113165
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.
    LaMontagne DS; Mugisha E; Pan Y; Kumakech E; Ssemaganda A; Kemp TJ; Cover J; Pinto LA; Safaeian M
    Vaccine; 2014 Oct; 32(47):6303-11. PubMed ID: 25218297
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
    Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
    J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparisons of VLP-Based ELISA, Neutralization Assays with Native HPV, and Neutralization Assays with PsV in Detecting HPV Antibody Responses in HIV-Infected Women.
    Du P; Brendle S; Milici J; Camacho F; Zurlo J; Christensen N; Meyers C
    J AIDS Clin Res; 2015 Mar; 6(3):. PubMed ID: 26085957
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HPV-specific antibodies in female genital tract secretions captured via first-void urine retain their neutralizing capacity.
    Téblick L; Lipovac M; Molenberghs F; Delputte P; De Vos WH; Vorsters A
    Hum Vaccin Immunother; 2024 Dec; 20(1):2330168. PubMed ID: 38567541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.